Postoperative simple biochemical markers for prediction of bone metastases in Egyptian breast cancer patients

被引:7
|
作者
Morcos, Nadia Y. S. [1 ]
Zakhary, Nadia I. [2 ]
Said, Mahmoud M. [1 ]
Tadros, May M. M. [1 ]
机构
[1] Ain Shams Univ, Dept Biochem, Fac Sci, Cairo, Egypt
[2] Cairo Univ, Natl Canc Inst, Dept Canc Biol, Cairo, Egypt
来源
ECANCERMEDICALSCIENCE | 2013年 / 7卷
基金
日本学术振兴会;
关键词
Breast cancer; bone metastasis; inflammation markers; vascularisation markers;
D O I
10.3332/ecancer.2013.305
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The present study was undertaken to identify patient populations at high risk for bone metastases (BM) at any time after diagnosis of operable breast cancer. Subjects and methods: A total number of 59 cases with breast cancer after mastectomy was subdivided into two main groups that included 30 patients with radiologically confirmed BM and 29 patients with no bone metastasis (NBM). Patients with NBM were formerly observed for a one-year follow-up interval to monitor the development of bone metastasis (new BM). Parameters included a full blood picture, tumour markers (carcinoembryonic antigen and CA 15.3) and some biochemical markers (vascular endothelial growth factor and zinc levels, as well as tartrate-resistant acid phosphatase and alkaline phosphatase activities). Results: A significant elevation was recorded in carcinoembryonic antigen level and alkaline phosphatase activity, as well as inflammation and vascularisation markers at the time of primary diagnosis in patients with BM, compared with those without BM. CA 15.3 was significantly higher in the new BM group as compared with the other two groups (patients free of bone metastasis [free BM] and BM). According to the likelihood ratio, a panel of single, calculated as well as combined markers was proposed to predict BM within one year in breast cancer patients. Conclusion: Vascularisation and inflammation markers, as well as CA 15.3 are predictive of bone recurrence within one year in breast carcinoma patients. We suggest that in cancer validation studies it is imperative to search for markers that link to the premetastatic process and to determine what type of mechanism is active in each stage.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Prediction of radiological response of bone metastases to therapy by biochemical marker monitoring in patients with breast cancer: A preliminary study
    Saip, P
    Yasasever, V
    Tenekeci, N
    Aydiner, A
    Inanc, S
    Onat, H
    Disci, R
    Topuz, E
    JOURNAL OF TUMOR MARKER ONCOLOGY, 1998, 13 (03): : 45 - 52
  • [22] Bone remodeling markers in the detection of bone metastases in breast cancer
    De la Piedra, C
    Ruibal, A
    García-Moreno, C
    Lefort, M
    Quiroga, I
    Rubert, M
    EUROMEDLAB 2003: PROCEEDINGS OF THE 15TH IFCC-FESCC EUROPEAN CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, : 311 - 314
  • [23] Retrospective Evaluation of Bone Turnover Markers in Serum for the Prediction of Metastases Development in Breast Cancer Patients: A Cohort Study
    Kasoha, Mariz
    Findeklee, Sebastian
    Nigdelis, Meletios P.
    Schmidt, Gilda
    Solomayer, Erich-Franz
    Hamoud, Bashar Haj
    BIOMEDICINES, 2024, 12 (06)
  • [24] The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load
    Generali, Daniele
    Berruti, Alfredo
    Tampellini, Marco
    Dovio, Andrea
    Tedoldi, Sara
    Bonardi, Simone
    Tucci, Marcello
    Allevi, Giovanni
    Aguggini, Sergio
    Milani, Manuela
    Bottini, Alberto
    Dogliotti, Luigi
    Angeli, Alberto
    BONE, 2007, 40 (01) : 182 - 188
  • [25] The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer
    Brown, JE
    Cook, RJ
    Major, P
    Lipton, A
    Lee, KA
    Zheng, M
    Hei, YJ
    Coleman, RE
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (09) : 1596 - 1596
  • [26] Intermediate study: Observational study about levels of biochemical markers of bone turnover in patients with breast cancer and bone metastases (ZOMAR study)
    De La Piedra, C.
    Tusquets, I.
    Gomez, P.
    Crespo, C.
    Calvo, L.
    Manso, L.
    Martinez, P.
    Ruiz-Borrego, M.
    Murias, A.
    Barnadas, A.
    BONE, 2011, 48 : S252 - S252
  • [27] Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer
    Mitsuru Koizumi
    Shunji Takahashi
    Etsuro Ogata
    Breast Cancer, 2003, 10 (1) : 21 - 27
  • [28] Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane
    Martinetti, A
    Bajetta, E
    Seregni, E
    Zilembo, N
    Ferrari, L
    Noberasco, C
    Massaron, S
    Rimassa, L
    Bombardieri, E
    TUMOR BIOLOGY, 1997, 18 (04) : 197 - 205
  • [29] Bone metabolism markers in breast cancer-patients with and without bone metastases - Baseline data
    Poeschl, Eva Maria
    Wehr, Elisabeth
    Schweighofer, Natascha
    Pock, Thomas
    Bauernhofer, Thomas
    Obermayer-Pietsch, Barbara
    WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (15-16) : A19 - A19
  • [30] BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH OSTEOLYSIS FROM BREAST-CANCER
    MONTI, M
    SCAZZOSO, A
    BEVILACQUA, M
    CALZAFERRI, G
    LOCATELLI, E
    CATANIA, S
    GANDINI, R
    CUNIETTI, E
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1990, 9 (03) : 145 - 150